New call-to-action
New call-to-action
New call-to-action

Foundation for Prader-Willi Blog | News

Categories

Top 10 Reasons to Attend the 2026 FPWR Prader-Willi Syndrome Conference in Philadelphia

Join us October 9–10 in Philadelphia for the annual FPWR Family Conference, a unique gathering dedicated to families and professionals affected by Prader-Willi syndrome. Over two powerful days, leading researchers, clinicians, and families from aroun...
March 18, 2026 Read More

Topics: News

New Study Opportunity for Prader-Willi Syndrome: Now Enrolling RM-718

A new clinical study is now enrolling individuals with Prader-Willi syndrome (PWS), offering families the opportunity to explore a potential new treatment for obesity and hyperphagia.
March 5, 2026 Read More

Topics: News, Clinical Trials Opportunities

Aardvark Therapeutics Announces Voluntary Pause of Hero Clinical Trial

SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the tr...
February 27, 2026 Read More

Topics: News

The Global PWS Registry: Turning Lived Experience Into Better Care

Families living with Prader-Willi syndrome are changing how PWS is understood, studied, and treated.
February 24, 2026 Read More

Topics: News, Research, Parents

The FPWR Therapeutic Accelerator Program: Bridging Research and Development

While much of FPWR’s work starts with discovery research, our mission extends across the full drug development pathway, supporting progress from foundational science all the way to potential treatments for Prader-Willi syndrome (PWS).
January 26, 2026 Read More

Topics: News

Pivotal Study Results of  VYKAT™ XR Published

Soleno Therapeutics has published results from its pivotal Phase 3 clinical study of VYKAT™ XR (diazoxide choline extended-release tablets, DCCR) in The Journal of Clinical Endocrinology and Metabolism, a peer-reviewed journal for endocrine and metab...
January 12, 2026 Read More

Topics: News

Your 2025 Impact: FPWR Fundraising Wrapped

Every breakthrough, every milestone, and every step forward in 2025 had one thing in common: our community. Because supporters like you showed up. You shared your story. You asked others to stand with you. And it mattered.
January 9, 2026 Read More

Topics: News

Global PWS Registry 2.0 Launches with New VYKAT Module

The Global PWS Registry is powered by the dedication of patients and families who share their PWS experiences. Each piece of data collected helps unlock insights that fuel scientific discoveries and treatment breakthroughs.
January 8, 2026 Read More

Topics: News

Positive Preliminary Results with Setmelanotide and Plans for Evaluation of RM-718 for PWS

Rhythm Pharmaceuticals has shared positive preliminary results from its exploratory Phase 2 trial of setmelanotide in people with PWS and announced, pending successful completion of this phase, plans to advance setmelanotide into a Phase 3 trial. Add...
December 18, 2025 Read More

Topics: News

About FPWR

The Foundation for Prader-Willi Research (federal tax id 31-1763110) is a nonprofit corporation with federal tax exempt status as a public charity under section 501(c)(3).

4star120x60

NORD_MembershipLogo_Platinum_2021

excellence-in-giving-logo

Main Menu

Our Mission

The mission of FPWR is to eliminate the challenges of Prader-Willi syndrome through the advancement of research and therapeutic development.

Contact Us

Foundation for Prader-Willi Research
Phone: 888-322-5487
Email: info@fpwr.org

FPWR
440 N Barranca Ave #3620
Covina, CA 91723

Copyright © 2020. All Rights Reserved. Terms of Use. Privacy Policy. Copyright Infringement Policy. Disclosure Statement.